Failure of oral bromocriptine to affect hypergastrinemia in two patients with the Zollinger-Ellison syndrome.
Bromocriptine was administered to 2 subjects with gastrin-secreting tumors of the pancreas. The absorption of the drug was confirmed by a rise in growth hormone levels but no change in the elevated serum gastrin levels were observed. Bromocriptine does not appear to affect gastrin hypersecretion in the way that it influences the hypersecretion of pituitary hormones.
D000236:Adenoma / Q000150:complications; D007516:Adenoma, Islet Cell / Q000150:complications; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D005755:Gastrins / Q000097:blood*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000150:complications; D010437:Peptic Ulcer / Q000150:complications; D015043:Zollinger-Ellison Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D005755:Gastrins; D001971:Bromocriptine; D013006:Growth Hormone